| Literature DB >> 30626355 |
L Aimola1, J Gordon-Brown2, A Etherington3, K Zalewska3, S Cooper3, M J Crawford2,3.
Abstract
BACKGROUND: Evidence is mounting that patient-reported experience can provide a valuable indicator of the quality of healthcare services. However, little is known about the relationship between the experiences of people with severe mental illness and the quality of care they receive. We conducted a study to examine the relationship between patient-reported experience and the quality of care provided to people with schizophrenia.Entities:
Keywords: Patient outcome measures; Patient satisfaction; Psychosis; Quality improvement
Mesh:
Year: 2019 PMID: 30626355 PMCID: PMC6327578 DOI: 10.1186/s12888-018-1998-y
Source DB: PubMed Journal: BMC Psychiatry ISSN: 1471-244X Impact factor: 3.630
Demographic characteristics of the patients included in the audit and of those who responded and did not respond to the survey
| Demographic characteristics | Patients included in the audit ( | Responders to the survey ( | Non responders ( | Difference in proportions (95% CI) | |
|---|---|---|---|---|---|
| Age mean (Standard Deviation) | 46 (13) | 51 (11) | 49 (12) | −2.0 (−5.3 to 1.4) | 0.249 |
| Gender n (%) | |||||
| Male | 3655 (65.2%) | 45 (73.8%) | 153 (63.8%) | 10.0 | 0.174 |
| Female | 1949 (34.8%) | 16 (26.2%) | 87 (36.3%) | (−3.5 to 21.3) | |
| Not stated | 4 (< 0.1%) | 0 (0.0%) | 0 (0.0%) | ||
| Ethnicity n (%) | |||||
| White | 4400 (78.5%) | 48 (78.7%) | 159 (66.3%) | 12.4 (−0.7 to 22.9) | 0.500 |
| Asian or Asian British | 446 (8.0%) | 3 (4.9%) | 21 (8.8%) | −3.8 (− 9.2 to 5.2) | |
| Black or Black British | 454 (8.1%) | 8 (13.1%) | 41 (17.1%) | −4.0 (−12.2 to7.5) | |
| Chinese or other | 108 (1.9%) | 1 (1.6%) | 6 (2.5%) | −0.9 (−6.4 to 4.0) | |
| Mixed | 116 (2.1%) | 0 (0.0%) | 5 (2.1%) | −2.1 (−4.8 to 4.0) | |
| Not stated | 84 (1.5%) | 1 (1.6%) | 8 (3.3%) | −1.69 (−5.6 to 5.1) | |
| Time since diagnosis | |||||
| Between 1 and 2 years | 226 (4.0%) | 0 (0.0%) | 4 (1.7%) | −1.7 (−4.4 to 4.2) | 0.183 |
| From 2 to 4 years | 495 (8.8%) | 3 (4.9%) | 22 (9.2%) | −4.3 (−9.6 to 4.9) | |
| From 4 to 10 years | 1353 (24.1%) | 12 (19.7%) | 67 (27.9%) | −8.2 (4.5 to −18.3) | |
| More than 10 years | 3534 (63.0%) | 46 (75.4%) | 147 (61.3%) | 14.1 (0.7 to 25.2) | |
| Care team n (%) | |||||
| Assertive Outreach | 689 (12.2%) | 3 (4.9%) | 17 (7.1%) | −2.2 (−6.8 to 7.3) | 0.085 |
| Community Team | 4035 (72.0%) | 57 (93.4%) | 194 (80.8%) | 12.6 (2.4 to 19.4) | |
| Crisis Resolution | 13 (0.2%) | 0 (0.0%) | 0 (0.0%) | – | |
| Early Intervention | 239 (4.3%) | 0 (0.0%) | 4 (1.7%) | −1.7 (−4.3 to 4.2) | |
| Other | 632 (11.3%) | 1 (1.6%) | 25 (10.4%) | −8.8 (−13.5 to 1.0) | |
a Data in these two columns refer only to the two trusts which collected information on responders and non-responders
Correlations between the global trust rating and its subgroups with patient satisfaction and patient experience
| Composite measure | Correlation coefficient ( | |
|---|---|---|
| Patient satisfaction | Patient-rated outcome | |
| Global trust rating | 0.209 (0.098) | 0.329** (0.008) |
| Physical health monitoring | 0.169 (0.182) | 0.199 (0.114) |
| Patient involvement | 0.149 (0.241) | 0.263* (0.036) |
| Pharmacotherapy | 0.106 (0.404) | 0.310* (0.013) |
| Psychotherapy | −0.024 (0.850) | −0.002 (0.990) |
| Care planning | 0.274* (0.029) | 0.026 (0.838) |
**p < 0.01
*p < 0.05
Fig. 1Scatterplot showing a positive linear correlation between global trust rating scores and patient-rated outcome scores among
List of the second round NAS standards
| Second round NAS standards | |
|---|---|
| S1 | Service users report that their experience of care over the past 12 months has been positive. |
| S2 | Service users report positive outcomes from the care they have received over the past 12 months. |
| S3 | Carers report satisfaction with the support and information they have been provided with to assist them in their role as a carer over the past 12 months. |
| S4 | The following physical health indicators have been monitored within the past 12 months: |
| S5 | When monitoring within the past 12 months has indicated a need for intervention, the following have been offered to the service user or the treating clinician has made a referral for the service user to receive: |
| S6 | The service user has been provided with evidence-based, written information (or an appropriate alternative), in an accessible format, about the antipsychotic drug that they are currently prescribed. |
| S7 | The service user was involved in deciding which antipsychotic was to be prescribed, after discussion of the benefits and potential side-effects. |
| S8 | The service user is currently only prescribed a single antipsychotic drug (unless they are in a short perioda of overlap while changing medication or because clozapine is co-prescribed with a second antipsychotic) and a rationale for this has been documented. |
| S9 | The current total daily dose of antipsychotic drug does not exceed the upper limit of the dose range recommended by the BNF. If it does, the rationale for this has been documented. |
| S10 | If there was no or inadequate response to the first antipsychotic drug prescribed after a minimum of 4wks at optimum doseb: |
| S11 | If there was no or inadequate response to the first antipsychotic drug within 8 weeks, part of which was at optimum doseb the first antipsychotic drug was stopped and a second antipsychotic drug given. |
| S12 | If there was no or inadequate response to two antipsychotic drugs, one of which should be a second-generation antipsychotic at optimum doseb, clozapine was offered. |
| S13 | If there was no or inadequate response to treatment despite an adequate trial of clozapinec, a second antipsychotic was given in addition to clozapine for a trial period of at least 8 weeks at optimum doseb. |
| S14 | a. CBT has been offered to all service users. |
| S15 | Each service user has a current care plan |
| S16 | Each service user knows how to contact services if in crisis |
a Short period: Up to 6 weeks
b Optimum dose: Up to three-quarters of BNF maximum or until side effects preclude further dose increase
c Adequate trial of clozapine: At least 8 weeks at optimum dose with clozapine plasma concentration checked